A practical reference on thymalfasin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
== Early life == On 20 August 2022, police announced the arrest of Brenda Cecilia Agüero (born 2 June 1995 in Buenos Aires); a nurse who worked in the neonatal unit and who had been among the suspended personnel during the initial investigation. Agüero lived with her mother and two sisters in the outskirts of Río Ceballos at the time of her arrest. Agüero graduated as a nurse with excellent results in 2018 and moved to Córdoba, where she worked at a private hospital between 2019 and December 2020, when she resigned to keep her only job at the Ramón Castillo Neonatal Hospital. Agüero denied the accusations and abstained from testifying. Days after her arrest, Agüero was formally charged with five counts of "aggravated murder for applying the insidious method of potassium incompatible with life" and eight counts of attempted murder. Agüero later accused a colleague of hers of the deaths, saying that this male nurse was present where the deaths occurred "all the time". During the legal proceedings, Agüero was incarcerated at the Bouwer prison in inner Córdoba, where she was isolated from other inmates to protect her from harm.
== Evidence == While good to moderate scientific evidence exists for several of the included training principles – e.g. the inclusion of elastic recoil as well as a training of proprioceptive refinement – there is currently insufficient evidence for the claimed beneficial effects of a fascia oriented exercises program as such, consisting of a combination of the above described four training elements. Self-myofascial release using a foam roller or roller massager pre- and post-exercise has been observed to decrease soreness due to DOMS. Self-myofascial release appears to have no negative effect on performance.
Prostatitis is inflammation of the prostate gland. It can be caused by infection with bacteria, or other noninfective causes. Inflammation of the prostate can cause painful urination or ejaculation, groin pain, difficulty passing urine, or constitutional symptoms such as fever or tiredness. When inflamed, the prostate becomes enlarged and is tender when touched during digital rectal examination. The bacteria responsible for the infection may be detected by a urine culture. Acute prostatitis and chronic bacterial prostatitis are treated with antibiotics. Chronic non-bacterial prostatitis, or male chronic pelvic pain syndrome is treated by a large variety of modalities including the medications alpha blockers, non-steroidal anti-inflammatories and amitriptyline, antihistamines, and other anxiolytics. Other treatments that are not medications may include physical therapy, psychotherapy, nerve modulators, and surgery. More recently, a combination of trigger point and psychological therapy has proved effective for category III prostatitis as well.
Pre-mature (early) cultivars are harvested before the end of July, serotinous (late) cultivars from September on, and mid-serotinous or mid-matutinal cultivars are in between these harvest times. Using pre-mature cultivars, rhizomes can be harvested earlier and sold for a higher price. Adlittoral (shallow), deep, and intermediate cultivars are distinguished according to the depth in which the rhizomes grow underground. Adlittoral cultivars range from 10 to 20 cm (3.9 to 7.9 in) depth and are often premature. They develop faster due to higher temperatures in surface soil layers. When harvested in July, adlittorals have higher yields than deeper-growing cultivars, but not necessarily when harvested in September. Rhizomes of adlittoral cultivars are crisp and good for frying purposes. Deep cultivars grow more than 40 cm (16 in) deep. They are often serotinous and can harvest high yields. Their rhizomes are starch-rich. The main popular Nelumbo nucifera cultivars in China are Elian 1, Elian 4, Elian 5, 9217, Xin 1, and 00–01. The average yield of these cultivars is 7.5–15 t/ha (3.3–6.7 tons/acre) of harvest in July and 30–45 t/ha (13–20 tons/acre) of harvest in September. In Australia, the cultivar grown for the fresh rhizome market in Guangdong and Japan, the common rhizome cultivars are Tenno and Bitchu.
Removal of interfibrillary proteins. Removal of keratin proteins. Collagen swelling due to the alkaline pH. Collagen fibre bundle splitting. Removal of natural grease and fats Liming operations of cattle hides usually last 18 hours and are generally associated with the alkaline phase of beamhouse operations.
Sources: en.wikipedia.org
=== Hardware === The technology made by Dionex includes the Rapid Separation LC (RSLC) and polymeric HPLC columns, a type of monolithic HPLC column. Unlike the inorganic silica columns, the polymer monoliths are made of an organic polymer base. Dionex, traditionally known for its ion chromatography capabilities, has led this side of the field. Dionex first acquired a license for the polymeric monolith technology in the 1990s. Dionex also acquired ESA Biosciences' HPLC assets in 2009, expanding its expertise in this area.
== Advocacy == Prior to gaining mainstream attention, Saladino was vegan. As an advocate of the strict meat only carnivore diet, Saladino argued that the diet could "cure everything ranging from depression to autoimmune conditions", and claimed that the diet cured his anxiety and eczema. He transitioned away from a strict carnivore diet by 2020 by adding carbohydrates to his diet, including fruit and honey. While on the carnivore diet, Saladino reported experiencing sleep disturbances, heart palpitations, muscle cramps, and a drop in testosterone levels. He said: "I started to think, maybe long-term ketosis is not great for me" and "probably not a great thing for most humans". Saladino's content often features him vlogging and presenting lifestyle advice and his personal routine, in scenarios varying from supermarket trips to surfing on his Costa Rican estate. He promotes the consumption of animal organs, claiming they help immunity, gut health, weight loss and bone strength. Saladino has urged his followers to use a bidet instead of toilet paper, claiming that toilet paper is "filled with hormone disrupting compounds" and that he avoids contact with them to "protect" his "hormonal health". According to Vice.com, during the Coronavirus pandemic, he was increasingly dismissive of the efficacy of vaccines contrary to mainstream scientific opinion, although saying they "may help avoid some severe COVID-19 complications." However, he asserted that "metabolic health" and "natural immunity" are more effective, also against medical consensus.
Blood sugar regulation is the process by which the level of blood sugar, the common name for glucose dissolved in blood plasma, is maintained by the body within a narrow range. This tight regulation is referred to as glucose homeostasis. Insulin, which lowers blood sugar, and glucagon, which raises it, are the most well known of the hormones involved, but more recent discoveries of other glucoregulatory hormones have expanded understanding of this process. The pancreas gland secretes two hormones that are primarily responsible for regulation of glucose levels in blood.
One study has found that these steroid-carrier complexes are bound by megalin, a membrane receptor, and are then taken into cells via endocytosis. One possible pathway is that once inside the cell these complexes are taken to the lysosome, where the carrier protein is degraded and the steroid hormone is released into the cytoplasm of the target cell. The hormone then follows a genomic pathway of action. This process is shown in Figure 2 to the right. The role of endocytosis in steroid hormone transport is not well understood and is under further investigation. In order for steroid hormones to cross the lipid bilayer of cells, they must overcome energetic barriers that would prevent their entering or exiting the membrane. Gibbs free energy is an important concept here. These hormones, which are all derived from cholesterol, have hydrophilic functional groups at either end and hydrophobic carbon backbones. When steroid hormones are entering membranes free energy barriers exist when the functional groups are entering the hydrophobic interior of membrane, but it is energetically favorable for the hydrophobic core of these hormones to enter lipid bilayers. These energy barriers and wells are reversed for hormones exiting membranes. Steroid hormones easily enter and exit the membrane at physiologic conditions. They have been shown experimentally to cross membranes near a rate of 20 μm/s, depending on the hormone. Though it is energetically more favorable for hormones to be in the membrane than in the ECF or ICF, they do in fact leave the membrane once they have entered it.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.